The International Collaboration on Cosmetics Safety enters a new chapter with the appointment of its 2026 Board officers, reinforcing its global commitment to advancing animal-free approaches in cosmetics safety science at a time of rapid regulatory and scientific change.
The International Collaboration on Cosmetics Safety (ICCS) has confirmed its 2026 Board officers after elections held during the organization’s December 2025 Board meeting, a milestone that underscores how this relatively young global initiative is solidifying its position in promoting scientifically robust, human‑relevant alternatives to animal testing in cosmetics safety assessment. The newly selected leadership reflects continuity as well as the organization’s growing sophistication, building on a year of significant accomplishments while positioning itself to expand its impact across regulatory, scientific, and industry communities worldwide.
ICCS operates at the intersection of science, policy, and collective engagement, bringing together a wide spectrum of stakeholders who pursue a common goal: promoting the global acceptance and implementation of animal-free safety science for cosmetics and their ingredients. The designation of the 2026 Board officers underscores the organization’s dedication to maintaining a strategic direction while adapting to an increasingly complex international landscape, where expectations related to ethical research, scientific rigor, and regulatory alignment continue to evolve.
Leadership continuity and global representation
The 2026 Board leadership brings together senior figures from across the cosmetics, consumer products, and regulatory advocacy sectors, reflecting the multi-stakeholder nature that has defined ICCS since its inception. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been re-elected as Chair of the Board of Directors. His reappointment signals confidence in a leadership approach that has emphasized scientific credibility, global cooperation, and constructive engagement with regulators.
Serving alongside him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose long-standing work in industry advocacy and regulatory engagement offers a valuable blend of regional insight and policy expertise. The role of Secretary will be held by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, bringing extensive knowledge of regulatory toxicology and international product safety systems. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been elected Treasurer, contributing significant leadership experience in toxicology and organizational governance.
Together, the officers constitute a leadership team whose background extends across multinational corporations, industry groups, and regulatory science, thereby strengthening ICCS’ role as a neutral forum for collaboration rather than a promoter of any individual sector. This equilibrium remains essential to the organization’s credibility, especially as it aims to shape regulatory perspectives and foster alignment on animal-free safety approaches.
Driving progress in animal-free science through collective collaboration
At the core of ICCS’ mission lies the conviction that animal-free safety assessment methods, when rigorously designed and validated, are not only ethically favorable but also scientifically stronger. Since its establishment in early 2023, ICCS has sought to show that non-animal approaches can deliver dependable, relevant insights to safeguard both human well-being and the environment. The confirmation of the 2026 Board officers arrives at a time when this message is gaining momentum, bolstered by concrete achievements and increasing involvement from regulators worldwide.
During 2025, ICCS delivered a series of initiatives that strengthened its scientific foundation and expanded its influence. Among these was the release of a Best Practice Guidance document, designed to provide clarity and consistency in the application of animal-free safety assessment approaches. This guidance aimed to bridge gaps between scientific innovation and regulatory expectations, offering a practical framework that stakeholders could reference when developing or evaluating non-animal data.
In parallel, ICCS supported the development of new methodologies aligned with next generation risk assessment (NGRA), an evolving paradigm that integrates advanced in vitro, in silico, and exposure-based approaches. These methodologies are increasingly viewed as essential to modern toxicology, offering the potential for more human-relevant insights while reducing reliance on animal testing. ICCS’ involvement in this space reflects its commitment to advancing not only ethical outcomes but also scientific excellence.
ICCS has also placed strong importance on open dialogue, and throughout 2025 the organization engaged widely with regulators, scientists, and policymakers in various regions, helping shape conversations about how animal-free data can be interpreted and integrated into current regulatory systems, a series of exchanges that has significantly advanced mutual understanding and confidence, especially in regions where the approval of non-animal approaches is still evolving.
A decisive turning point in cosmetics safety oversight
The appointment of the 2026 Board officers takes place against a backdrop of significant change in global cosmetics regulation. Many markets are reassessing long-standing testing requirements, responding to public expectations, scientific advances, and international policy trends. In this context, organizations like ICCS play a critical role in helping align innovation with regulation, ensuring that progress is both credible and sustainable.
ICCS leadership has consistently emphasized that progress in animal-free safety science cannot arise from isolated efforts; instead, it requires coordinated action among industry, academia, regulators, and civil society. This perspective is reflected in the composition of the Board, which brings together leaders who understand the technical, regulatory, and organizational dimensions necessary to foster significant transformation.
Statements from ICCS leadership following the elections highlighted both confidence and realism. While there is recognition of the momentum generated in recent years, there is also acknowledgment that significant work remains. Achieving widespread regulatory acceptance of animal-free approaches will require continued investment in research, transparent data sharing, and ongoing engagement with authorities to address legitimate questions around reliability, applicability, and protection of public health.
The re-elected Chair emphasized the importance of leveraging ICCS’ global, multi-stakeholder model to close the gap between innovation and regulation. This approach aims to ensure that advances in animal-free science are not confined to research settings but translated into practical tools that regulators can trust and apply consistently.
Strengthening foundations for long-term impact
As ICCS moves toward 2026 and the years that follow, the organization aims to reinforce its progress while broadening its influence, and the newly appointed Board leadership is anticipated to guide key priorities that balance scientific aspirations with practical execution, including pinpointing topics that require further direction or consensus, backing the validation and dissemination of emerging methodologies, and promoting global harmonization to minimize fragmentation among regulatory expectations.
Education stands as another fundamental component of ICCS’ strategy. By offering accessible, science-grounded materials and spaces for dialogue, the organization seeks to clarify animal-free safety science and support well-informed choices. This remains crucial in a discipline where misunderstandings or uneven knowledge can hinder advancement, even when the core science is robust.
The organization’s structure, which includes market-leading cosmetics and ingredient manufacturers, trade and research associations, and animal protection organizations, positions it uniquely to address these challenges. This diversity of perspectives helps ensure that discussions remain grounded, balanced, and focused on shared goals rather than narrow interests.
Headquartered in New York, ICCS continues to operate as a global initiative, reflecting the inherently international nature of cosmetics development and regulation. Products and ingredients often move across borders, making harmonization and mutual recognition of safety approaches increasingly important. Through its collaborative model, ICCS seeks to contribute to this harmonization, reducing duplication and fostering trust in animal-free science worldwide.
By confirming its 2026 Board officers, ICCS underscores both consistency and a clear drive toward progress, with a leadership group that extends the momentum of a year defined by tangible accomplishments while offering the insight and expertise required to steer the coming stage of transformation; as scientific innovation quickens and regulatory expectations shift, the organization’s function as a unifying force and driver of animal-free cosmetics safety science is poised to gain even greater significance.
Ultimately, the significance of the 2026 Board elections lies not only in the individuals appointed, but in what their leadership represents: a sustained commitment to collaboration, scientific integrity, and the responsible advancement of alternatives to animal testing. For ICCS and its stakeholders, the coming years offer an opportunity to translate vision into lasting impact, shaping the future of cosmetics safety in a way that aligns ethics, science, and global public trust.
